Gocovri (Adamas Pharmaceuticals) is an extended-release formulation of amantadine, uniquely indicated for the treatment of levodopa-induced dyskinesia (LID) in Parkinson’s disease. While amantadine has been available as an anti-Parkinson drug since 1968, the specific formulation in Gocovri was approved in August 2017 following investigations into the effect of N-methyl-D-aspartate receptor antagonists on dyskinesia. Gocovri is administered once daily at bedtime, allowing for amantadine levels to slowly increase during the night and peak in the early morning, when dyskinesia episodes are most frequent.
LIST OF FIGURES
9 Figure 1: Gocovri for Parkinson’s disease – SWOT analysis
10 Figure 2: Datamonitor Healthcare’s drug assessment summary of Gocovri for Parkinson’s disease
11 Figure 3: Datamonitor Healthcare’s drug assessment summary of Gocovri for Parkinson’s disease
13 Figure 4: Gocovri sales for Parkinson’s disease in the US, 2016–25
LIST OF TABLES
5 Table 1: Gocovri drug profile
7 Table 2: Gocovri pivotal trial data in Parkinson’s disease
13 Table 3: Gocovri sales for Parkinson’s disease in the US ($m), 2016–25
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.